β(2)-microglobulin Normalization Within 6 months of Ibrutinib-based Treatment is Associated with Superior PFS in CLL

High pre-treatment β(2)-microglobulin (B2M) level is associated with inferior survival outcomes. However, the prognostic and predictive significance of changes in B2M during treatment have not been reported. We analyzed 83 patients treated with ibrutinib-based regimens (66 relapsed/refractory) and 1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer
Hauptverfasser: Thompson, Philip A., O’Brien, Susan M., Xiao, Lianchun, Wang, Xuemei, Burger, Jan A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4813299/
https://ncbi.nlm.nih.gov/pubmed/26588193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29794
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge